Market Research Logo

Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Summary

The women’s health market represents a small but growing therapy area. There are currently 277 pipeline products in active development for women’s health, making it the 16th largest therapy area by pipeline size. Key indications within the area include endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia, menopausal disorders and infertility.

The global market is projected to grow at a compound annual growth rate (CAGR) of 5.16% till 2024. This relatively strong growth will be driven by a number of factors. These include the strong growth projected for human papillomavirus (HPV) vaccines, which are administered to girls and women in order to prevent development of CIN, an abnormality of the cells on the surface of the cervix, which can progress to cervical cancer in some cases.

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

Some 246 licensing deals have been completed within the women’s health therapy area since 2006, demonstrating a relatively high level of activity, considering the small size of the therapy area. Co-development deal activity has been much lower, with only 78 deals completed since 2006.

The strategic consolidations landscape was largely dominated by small molecule products and products acting on G-protein coupled receptors (GPCR). The majority of deals identified were relatively low value although a small number of deals exceeded $500m in value, demonstrating that women’s health products are capable of attracting high levels of investment.

The report Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

Scope

  • There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
  • Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
  • Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
  • The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
  • In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?
Reasons to buy
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
  • Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
  • Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Therapy Area Overview
      • Endometriosis
      • Polycystic Ovarin Syndrome
      • Cervical Intraepithelial Neoplasia
        • Table Women's Health Drugs Market, Global, Classification of Cervical Intraepithelial Neoplasia, 2018
      • Menopausal Disorders
      • Infertility
    • Symptoms
      • Endometriosis
      • Polycystic Ovarian Syndrome
      • Cervical Intraepithelial Neoplasia
      • Menopausal Disorders
        • Table Women's Health Drugs Market, Common Symptoms of the Perimenopause and Menopause, 2018
      • Infertility
    • Diagnosis
      • Endometriosis
      • Polycystic Ovarian Syndrome
        • Table Women's Health Drugs Market, Global, Comparison of PCOS Diagnostic Criteria Classification Systems, 2018
      • Cervical Intraepithelial Neoplasia
      • Menopausal Disorders
      • Infertility
    • Etiology and Epidemiology
      • Table Women's Health Drugs Market, 7MM, Prevalence of Endometriosis, Polycystic Ovarian Syndrome, and Women's Infertility, 2017
      • Endometriosis
        • Table Figure 1: Women's Health Drugs Market, 7MM, Epidemiology Patterns for Endometriosis, 2017–2024
      • Polycystic Ovarian Syndrome
        • Table Figure 2: Women's Health Drugs Market, 7MM, Epidemiology Patterns for Polycystic Ovarian Syndrome, 2017–2024
      • Cervical Intraepithelial Neoplasia
      • Menopause
      • Infertility
        • Table Figure 3: Women's Health Drugs Market, 7MM, Epidemiology Patterns for Infertility, 2017–2024
    • Pathophysiology
      • Endometriosis
      • Polycystic Ovarian Syndrome
      • Cervical Intraepithelial Neoplasia
    • Co-morbidities and Complications
      • Endometriosis
      • Polycystic Ovarian Syndrome
      • Cervical Intraepithelial Neoplasia
      • Menopause and Menopausal Disorders
      • Infertility
    • Treatment
      • Treatment Options
        • Table Women's Health Drugs Market, Global, Types of Female Contraceptives, 2018
  • Key Marketed Products
    • Overview
      • Table Figure 4: Women's Health Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
    • Premarin family (conjugated estrogens) – Pfizer
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Premarin, 2018
      • Table Figure 5: Women's Health Drugs Market, Global, Annual Revenue for Premarin ($bn), 2006–2024
    • Lupron/Lupron Depot (leuprolide acetate SR) - AbbVie
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Lupron/Lupron Depot, 2018
      • Table Figure 6: Women's Health Drugs Market, Global, Annual Revenue for Lupron ($bn), 2006–2024
    • Gonal-F (follitropin alfa) - Merck KGaA
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Gonal-F, 2018
      • Table Figure 7: Women's Health Drugs Market, Global, Annual Revenue for Gonal-F ($m), 2017– 2024
    • Mirena (levonorgestrel) - Bayer
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Mirena, 2018
      • Table Figure 8: Women's Health Market, Global, Annual Revenue for Mirena ($bn), 2006–2024
    • Celebrex (celecoxib) - Pfizer
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Celebrex, 2018
      • Table Figure 9: Women's Health Drugs Market, Global, Annual Revenue for Celebrex ($bn), 2006–2024
    • Implanon/Nexplanon (etonogestrel) - Merck & Co.
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Implanon ,2018
      • Table Figure 10: Women's Health Drugs Market, Global, Annual Revenue for Implanon/Nexplanon ($m), 2007–2024
    • Yasmin/Yaz (drospirenone and ethinylestradiol) - Bayer
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Yasmin/Yaz, 2018
      • Table Figure 11: Women's Health Drugs Market, Global, Annual Revenue for Yasmin/Yaz ($bn), 2006–2024
    • Nuvaring (ethinylestradiol and etonogestrel) - Merck & Co
      • Table Women's Health Drugs Market, Global, Approved Health Indications for Nuvaring, 2018
      • Table Figure 12: Women's Health Drugs Market, Global, Annual Revenue for Nuvaring ($m), 2006–2024
    • Gardasil – Merck and Co
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Gardasil, 2018
      • Table Figure 13: Women's Health Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2017–2023
    • Esmya (ulipristal acetate) – Gedoen Richter/Allergan
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Esmya, 2018
      • Table Figure 14: Women's Health Drugs Market, Global, Annual Revenue for Esmya ($bn), 2013– 2024
    • Orilissa (elagolix sodium) – AbbVie
      • Table Women's Health Drugs Market, Global, Approved Women's Health Indications for Orilissa, 2018
      • Table Figure 15: Women's Health Drugs Market, Global, Annual Revenue for Orilissa ($bn), 2018– 2024
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 16: Women's Health Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
    • Pipeline Development Landscape
      • Table Figure 17: Women's Health Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018
      • Table Figure 18: Women's Health Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018
      • Table Figure 19: Women's Health Market, Global, Pipeline for Key Indications by Molecule Type, 2018
    • Molecular Targets in the Pipeline
      • Table Figure 20: Women's Health Drugs Market, Global, Pipeline by Molecular Target, 2018
      • Table Figure 21: Women's Health Drugs Market, Global, Pipeline for Key Indications by Molecular Target Class, 2018
    • Clinical Trials Landscape
      • Clinical Trial Failure Rates
        • Table Figure 22: Women's Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development (%), 2006–2018
        • Table Figure 23: Women's Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006–2018
        • Table Figure 24: Women's Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006–2018
        • Table Figure 25: Women's Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target Class (%), 2006–2018
      • Clinical Trial Duration
        • Table Figure 26: Women's Health Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018
        • Table Figure 27: Women's Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2018
        • Table Figure 28: Women's Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2018
        • Table Figure 29: Women's Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target Class (months), 2006–2018
      • Clinical Trial Size
        • Table Figure 30: Women's Health Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018
        • Table Figure 31: Women's Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2018
        • Table Figure 32: Women's Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2018
        • Table Figure 33: Women's Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2018
      • Cumulative Clinical Trial Size
        • Table Figure 34: Women's Health Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018
        • Table Figure 35: Women's Health Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2018
        • Table Figure 36: Women's Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2018
        • Table Figure 37: Women's Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2018
    • Assessment of Key Pipeline Products
      • Relugolix – Takeda Pharmaceutical Co. Ltd
        • Table Figure 38: Women's Health Drugs Market, Global, Revenue Forecast for Relugolix ($m), 2021–2024
      • Bremelanotide – AMAG Pharmaceuticals Inc
        • Table Figure 39: Women's Health Drugs Market, Global, Annual Revenue Forecast for Bremelanotide ($m), 2019–2024
      • SAGE-217 – Sage Therapeutics Inc.
        • Table Figure 40: Women's Health Drugs Market, Global, Revenue Forecast for SAGE-217 ($m), 2019–2024
      • Fezolinetant – Ogeda SA
        • Table Figure 41: Women's Health Drugs Market, Global, Annual Revenue Forecast for Fezolinetant ($m), 2021–2024
      • Zulresso – Sage Therapeutics
        • Table Figure 42: Women's Health Drugs Market, Global, Revenue Forecast for Zulresso ($m), 2019–2024
      • Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid – Inovio Pharmaceuticals Inc
        • Table Figure 43: Women's Health Drugs Market, Global, Revenue Forecast for Bizalimogene Ralaplasmid and Mavilimogene Ralaplasmid ($m), 2021–2024
      • Retosiban – GlaxoSmithKline
        • Table Figure 44: Women's Health Drugs Market, Global, Revenue Forecast for Retosiban ($m), 2019–2024
  • Multi-scenario Market Forecast to 2024
    • Overall Market Size
      • Table Figure 45: Women's Health Drugs Market, Global, Market Size ($bn), 2017–2024
      • Table Women's Health Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017–2024
    • Generic Penetration
      • Table Figure 46: Women's Health Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024
    • Revenue Forecast by Molecular Target Class
      • G Protein-Coupled Receptor
        • Table Figure 47: Women's Health Market, Global, Annual Revenue Forecast for G Protein- Coupled Receptor Target Class ($bn), 2017–2024
      • Nuclear Receptor
        • Table Figure 48: Women's Health Drugs Market, Global, Annual Revenue Forecast for Nuclear Receptor Target Class ($bn), 2017–2024
      • Pathogen
        • Table Figure 49: Women's Health Drugs Market, Global, Annual Revenue Forecast for Pathogen Target Class ($bn), 2017–2024
      • Ion Channels/Transporter
        • Table Figure 50: Women's Health Drugs Market, Global, Annual Revenue Forecast for Ion Channels/Transporters ($bn), 2017–2024
  • Company Analysis and Positioning
    • Table Figure 51: Women's Health Drugs Market, Global, Company Analysis Matrix, 2017–2024
    • Table Figure 52: Women's Health Market, Global, Companies by CAGR and Market Share, 2017–2024
    • Revenue and Market Share Analysis by Company
      • Table Women's Health Drugs Market, Global, Forecast Revenue by Company, 2017–2024
      • Table Figure 53: Women's Health Drugs Market, Global, Market Share by Company (%), 2017–2024
      • Table Figure 54: Women's Health Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024
      • Table Figure 55: Women's Health Market, Global, Revenues by Route of Acquisition, 2017–2024
      • Bayer AG – Company to Remain a Market Leader within Women's Health
        • Table Figure 56: Women's Health Drugs Market, Global, Bayer AG Annual Revenue Forecast ($bn), 2017–2024
      • AbbVie Inc – Orilissa to Reach Blockbuster Status, Boosting Company's Market Share
        • Table Figure 57: Women's Health Market, Global, AbbVie Inc Annual Revenue Forecast ($bn), 2017–2024
      • Allergan – Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
        • Table Figure 58: Women's Health Market, Global, Allergan Plc Annual Revenue Forecast ($bn), 2017–2024
      • Merck & Co. – Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
        • Table Figure 59: Women's Health Market, Global, Merck& Co. Annual Revenue Forecast ($bn), 2017–2024
      • GlaxoSmithKline – Cervarix and Retosiban to Drive Strong Growth
        • Table Figure 60: Women's Health Market, Global, GlaxoSmithKline Annual Revenue Forecast ($m), 2016–2023
      • Pfizer – How will patent expiration affect revenues for women's health market?
        • Table Figure 61: Women's Health Market, Global, Pfizer Annual Revenue Forecast ($bn), 2017– 2024
      • TherapeuticsMD – Women's Health Specialist to Gain Considerable Market Share by 2024
        • Table Figure 62: Women's Health Market, Global, TherapeuticsMD Annual Revenue Forecast ($bn), 2017–2024
    • Company Landscape
      • Table Figure 63: Women's Health Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 64: Women's Health Drugs Market, Global, Overall, High-Activity and Late-Stage Developers by Level of Women's Health Specialization, 2018
      • Table Figure 65: Women's Health Drugs Market, Global, Proportion of Total Company Revenue Attributed to Women's Health, 2017–2024
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Value and Year
        • Table Figure 66: Women's Health Drugs Market, Global, Licensing Deals by Region, Value and Year, 2006–2018
      • Deals by Key Indication
        • Table Figure 67: Women's Health Drugs Market, Global, Licensing Deals by Indication, 2006–2018
      • Deals by Stage of Development and Value
        • Table Figure 68: Women's Health Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 69: Women's Health Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018
      • Licensing Deals with Disclosed Values
        • Table Figure 70: Women's Health Drugs Market, Global, Licensing Deals with Disclosed Deal Values, 2018
    • Co-development Deals
      • Deals by Region, Value and Year
        • Table Figure 72: Women's Health Drugs Market, Global, Co-development Deals by Region, Value and Year, 2006–2018
      • Deals by Key Indication
        • Table Figure 73: Women's Health Drugs Market, Global, Co-development Deals by Indication, 2006–2018
      • Deals by Stage of Development and Value
        • Table Figure 74: Women's Health Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018
      • Deals by Molecule Type, Molecular Target and Value
        • Table Figure 75: Women's Health Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018
      • Co-development Deals with Disclosed Values
        • Table Figure 76: Women's Health Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2018
  • Appendix
    • References
    • Abbreivations
    • List of All Pipeline Products
      • Table Figure 77: Women's Health Drugs Market, Global, All Pipeline Products, 2018
    • Disease List
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report